REFLUX ESOPHAGITIS IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME

被引:121
作者
MILLER, LS [1 ]
VINAYEK, R [1 ]
FRUCHT, H [1 ]
GARDNER, JD [1 ]
JENSEN, RT [1 ]
MATON, PN [1 ]
机构
[1] NIDDKD,DIGEST DIS BRANCH,BLDG 10,ROOM 9C-103,BETHESDA,MD 20892
基金
美国国家卫生研究院;
关键词
D O I
10.1016/0016-5085(90)90823-J
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The incidence of ulcers of the stomach and duodenum and their response to medical therapy, in patients with Zollinger-Ellison syndrome is well described. However, reflux esophagitis is less well recognized. In this study we determined the frequency of reflux esophagitis in 122 patients with Zollinger-Ellison syndrome and examined their response to medical therapy. Esophageal symptoms, endoscopic abnormalities, or both were present in 61% of patients. Forty-five percent of patients had esophageal symptoms consisting of heartburn, dysphagia, or both. Forty-three percent of patients had endoscopic abnormalities of the esophagus, and 23% demonstrated moderate or severe disease. When sufficient antisecretory medication was administered to lower gastric acid secretion to < 10 mEq/h in the last hour before the next dose of drug, 67% of the patients with reflux esophagitis responded with complete disappearance of symptoms and normalization of the endoscopic abnormalities. The other 33% of patients required an increase in medication to lower acid output to < 5 mEq/h in 7% and < 1 mEq/h in the other 26% to resolve symptoms and signs completely. We conclude that reflux esophagitis occurs in the majority of patients with Zollinger-Ellison syndrome and responds well to medical therapy, although one third of patients require intensive antisecretory medication. © 1990.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 28 条
[1]  
BONFILS S, 1970, PROGRESS GASTROENTER, V2, P332
[2]   RANITIDINE - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN PEPTIC-ULCER DISEASE AND OTHER ALLIED DISEASES [J].
BROGDEN, RN ;
CARMINE, AA ;
HEEL, RC ;
SPEIGHT, TM ;
AVERY, GS .
DRUGS, 1982, 24 (04) :267-303
[3]  
CAMERON AJ, 1974, MAYO CLIN PROC, V49, P44
[4]  
CASTELL DO, 1985, GASTROESOPHAGEAL REF
[5]   OMEPRAZOLE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN PEPTIC-ULCER DISEASE AND ZOLLINGER-ELLISON SYNDROME [J].
CLISSOLD, SP ;
CAMPOLIRICHARDS, DM .
DRUGS, 1986, 32 (01) :15-47
[6]   DIFFERENCES IN HEALING TENDENCY OF REFLUX ESOPHAGITIS WITH OMEPRAZOL AND RANTIDINE - RESULTS OF AN AUSTRIAN-GERMAN-SWISS MULTICENTER TRIAL [J].
DAMMANN, HG ;
BLUM, AL ;
LUX, G ;
REHNER, M ;
RIECKEN, EO ;
SCHIESSEL, R ;
WIENBECK, M ;
WITZEL, L ;
BERGER, J .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, 111 (04) :123-128
[7]  
DEHN TCB, 1988, GUT, V29, pA1440
[8]   ZOLLINGER-ELLISON SYNDROME - RE-APPRAISAL + EVALUATION OF 260 REGISTERED CASES [J].
ELLISON, EH ;
WILSON, SD .
ANNALS OF SURGERY, 1964, 160 (03) :512-&
[9]   OMEPRAZOLE AND RANITIDINE IN TREATMENT OF REFLUX ESOPHAGITIS - DOUBLE-BLIND COMPARATIVE TRIAL [J].
HAVELUND, T ;
LAURSEN, LS ;
SKOUBOKRISTENSEN, E ;
ANDERSEN, BN ;
PEDERSEN, SA ;
JENSEN, KB ;
FENGER, C ;
HANBERGSORENSEN, F ;
LAURITSEN, K .
BRITISH MEDICAL JOURNAL, 1988, 296 (6615) :89-92
[10]   FAMOTIDINE, A NEW, POTENT, LONG-ACTING HISTAMINE H2-RECEPTOR ANTAGONIST - COMPARISON WITH CIMETIDINE AND RANITIDINE IN THE TREATMENT OF ZOLLINGER-ELLISON SYNDROME [J].
HOWARD, JM ;
CHREMOS, AN ;
COLLEN, MJ ;
MCARTHUR, KE ;
CHERNER, JA ;
MATON, PN ;
CIARLEGLIO, CA ;
CORNELIUS, MJ ;
GARDNER, JD ;
JENSEN, RT .
GASTROENTEROLOGY, 1985, 88 (04) :1026-1033